<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289756</url>
  </required_header>
  <id_info>
    <org_study_id>IKP237</org_study_id>
    <secondary_id>2009-014531-20</secondary_id>
    <nct_id>NCT01289756</nct_id>
  </id_info>
  <brief_title>Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene</brief_title>
  <official_title>Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Bosch Gesellschaft für Medizinische Forschung mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Robert Bosch Gesellschaft für Medizinische Forschung mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is the clinical validation of the metabolism and the pharmakokinetic of
      Clomifen in correlation to CYP2D6 and inhibition of CYP3A4.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)of clomiphene</measure>
    <time_frame>1, 2, 4, 6, 8, 10, 12, 24, 72 and 168 hours after durg application</time_frame>
    <description>AUC of clomiphene and metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)of Clomiphene</measure>
    <time_frame>1, 2, 4, 6, 8, 10, 12, 24, 72 and 168 hours after drug application</time_frame>
    <description>Cmax of Clomiphene and metabolites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of Clomiphene</measure>
    <time_frame>4, 8, 12 and 24 hours after drug application</time_frame>
    <description>Clearance of Clomiphene and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic</measure>
    <time_frame>4, 8, 12 and 24 hours after drug application</time_frame>
    <description>Metabolomic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of clomiphene</measure>
    <time_frame>4, 8, 12, 24 hours after drug application</time_frame>
    <description>Tmax of clomiphene and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenomics</measure>
    <time_frame>once</time_frame>
    <description>Pharmacogenomics</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Anovulation</condition>
  <condition>Disorder Due Cytochrome P450 CYP2D6 Variant</condition>
  <condition>Cytochrome P450 CYP3A Enzyme Deficiency</condition>
  <arm_group>
    <arm_group_label>CYP2D6 EM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 PM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 UM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene</intervention_name>
    <description>clomiphene once 100 mg oral</description>
    <arm_group_label>CYP2D6 EM</arm_group_label>
    <arm_group_label>CYP2D6 IM</arm_group_label>
    <arm_group_label>CYP2D6 PM</arm_group_label>
    <arm_group_label>CYP2D6 UM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene and paroxetine</intervention_name>
    <description>clomiphene 100mg and paroxetine 3x40mg</description>
    <arm_group_label>CYP2D6 EM</arm_group_label>
    <arm_group_label>CYP2D6 IM</arm_group_label>
    <arm_group_label>CYP2D6 PM</arm_group_label>
    <arm_group_label>CYP2D6 UM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene and clarithromycin</intervention_name>
    <description>clomiphene 100mg and clarithromycin 9x500mg</description>
    <arm_group_label>CYP2D6 EM</arm_group_label>
    <arm_group_label>CYP2D6 IM</arm_group_label>
    <arm_group_label>CYP2D6 PM</arm_group_label>
    <arm_group_label>CYP2D6 UM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Female caucasians

          -  Age 18 - 45 years old

          -  BMI 18.5 - 26 kg/m2

        Exclusion Criteria:

          -  Persons with known sensitivity of Clomifen and/or Paroxetine and/or Clarithromycin

          -  Pregnancy/lactation period

          -  Meno-/postmenopausal

          -  Smokers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Schwab, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tuebingen</name>
      <address>
        <city>Stuttgart</city>
        <state>BW</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Robert Bosch Gesellschaft für Medizinische Forschung mbH</investigator_affiliation>
    <investigator_full_name>Matthias Schwab</investigator_full_name>
    <investigator_title>Prof. M.D.</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>clomiphene</keyword>
  <keyword>CYP2D6 polymorphisms</keyword>
  <keyword>inhibition of CYP2D6 and CYP3A4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

